NBIX:NASDAQ
Neurocrine Biosciences, Inc
USD 142.25
arrow_downward
-1.19%(-1.71) 1H
USD 142.25
0.00% (0.00)
bedtimeSelepas waktu pejabat
Ditutup: 22 Sep, 4:00:00 PTG GMT-4 · USD
search
Semua simbol
1H
5H
1B
6B
TSS
1T
5T
MAKS
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk NBIX...
Buka
USD 144.17
Tinggi
USD 144.26
Rendah
USD 141.78
Permodalan Pasaran
14.46B
Purata volum
1.17J
Volum
1.21J
Nisbah H/P
20.85
tgi 52 mgu
USD 186.12
rdh 52 mgu
USD 122.14
EPS
USD 6.82
Beta
0.38
Syer tertunggak
101.65J
Bilangan pekerja
2K
Buka
USD 144.17
Tinggi
USD 144.26
Rendah
USD 141.78
Permodalan Pasaran
14.46B
Purata volum
1.17J
Volum
1.21J
Nisbah H/P
20.85
tgi 52 mgu
USD 186.12
rdh 52 mgu
USD 122.14
EPS
USD 6.82
Beta
0.38
Syer tertunggak
101.65J
Bilangan pekerja
2K
Profil
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Perihal Neurocrine Biosciences, Inc
CEOKevin C. Gorman
Pekerja2.5K
Diasaskan1992
Ibu pejabatSan Diego, California, Amerika Syarikat
Sektor-
Laman webneurocrine.com